Acute myeloïde leukemie (AML)
HOVON 156: A phase 3, multicenter, open-label, randomized study of gilteritinib versus midostaurin in combination with induction and consolidaton therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Chronische myeloïde leukemie (CML)
HOVON 142: Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing nilotinib versus imatinib with switch to nilotinib in absence of optimal response
Myelodysplastisch syndroom (MDS)
IMerge 2: A study to evaluate imetelstat (GRN163L) in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment
Myeloproliferatieve neoplasieën (MPN)
FREEDOM 2: A phase III, multi center, open-lable, randomized study to evaluate the efficacy and safety of fedratinib compared to best avaiable therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycytemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
Supportive care
REDDS2: A randomised feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes
F2G: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options
CLARITY: Cardiotoxicity and other late effects after radiotherapy and immuno-chemotherapy for non-Hodgkin lymphoma
Hemoglobinopathie
SCORE: Sickle cell outcome research
Ga terug naar de algemene homepage Studieinformatie.